Ane Appelt: Short course RT vs chemorad for organ preservation in early stage rectal cancer
Ane Appelt, Associate Professor in Radiotherapy Physics at the University of Leeds, shared a post on LinkedIn:
“I’m SO delighted to finally see first STAR-TREC data reported.
Short course RT vs chemorad for organ preservation in early stage rectal cancer: 61% vs 80% TME-free survival at 12 months.
More organ preservation with long-course chemorad!
This has been an immense effort by the trial investigators David Sebag-Montefiore, Corrie Marijnen, Simon Bach, Hans Wilt de (and many others).
As jointly RT-responsible, I’m particularly delighted that the discussant Maria Antonietta Gambacorta recognised that reduced mesorectal-only treatment volumes should now be integrated into standard treatment guidelines for early rectal cancer.”
More posts featuring Ane Appelt.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023